Adavanced Glycated Endproducts and Development of CAD
- Conditions
- AtherosclerosisInflammation
- Registration Number
- NCT02089360
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Brief Summary
Blood sample is prospectively taken from consecutive patients underwent coronary angiogram in our center, after getting informed consent from the patients. Serum level of advanced glycation end products (AGEs) was measured and the clinical features of patients (including angiographic results) were entered into our database. Clinical follow-up was performed for all patients, and the relationship between AGEs and paitents' outcome were analyzed. Further intervention will be adjusted according to the results,including clinical and basic research in lab.
- Detailed Description
Serum levels of HMGB1, HMGB2, ADAM10, etc. will be measured in lab and animal studies will be designed to intervene the adverse interaction between abnormal serum concentration of AGEs, etc. and worse clinical results.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10000
- patients underwent coronary angiogram for suspected coronary artery disease and potential percutaneous coronary intervention
- patients underwent coronary angiogram for other reasons, including pre-surgery examination
- patients with severe co-morbidity, and life expectancy less than one-year
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MACE 5-year including death, occurrence of myocardial infarction, and coronary revascularization
- Secondary Outcome Measures
Name Time Method progression in coronary atherosclerosis 5-year repeated coronary angiogram in patients with symptom aggravation or occurrence of myocardial infarction, to evaluate the progression of coronary lesions, comparing to the baseline results.
Trial Locations
- Locations (1)
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai, Shanghai, China